---
title: "Science Sun Pharm's subsidiary has received the clinical trial approval notice for the drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/232047700.md"
description: "According to the Zhitong Finance APP, Science Sun Pharm announced that its subsidiary Shenyang Junyuan Pharmaceutical Co., Ltd. has received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration, agreeing to conduct clinical trials for the treatment of mammary hyperplasia, with the drug name being Danxiang Granules"
datetime: "2025-03-17T08:09:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/232047700.md)
  - [en](https://longbridge.com/en/news/232047700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/232047700.md)
generator: "portal-rs"
---

# Science Sun Pharm's subsidiary has received the clinical trial approval notice for the drug

According to the Zhitong Finance APP, Science Sun Pharm (300485.SZ) announced that its subsidiary Shenyang Junyuan Pharmaceutical Co., Ltd. has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, agreeing to conduct clinical trials for the treatment of mammary hyperplasia, with the drug name being Danxiang Granules

### Related Stocks

- [300485.CN](https://longbridge.com/en/quote/300485.CN.md)

## Related News & Research

- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [BioArctic, Mesenkia partner to develop BrainTransporter-enabled antibody for glioblastoma](https://longbridge.com/en/news/296330014.md)
- [Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study](https://longbridge.com/en/news/296068059.md)
- [Innovotech Inc. Reports Q2 2026 Financial Results](https://longbridge.com/en/news/296265304.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**